HEMODİYALİZ HASTALARINDA PLAZMA MALONDİALDEHİT VE TİYOL SEVİYELERİ

Abstract

Kronik böbrek yetmezliği hastalarında ve özellikle diyaliz tedavisi alanlarda gözlenen yüksek kardiyovasküler hastalık (KVH) riskinin, oksidatif stresle ilişkisini araştırmak amacıyla; yaşları 16-64 yıl arasında değişen toplam 42 hemodiyaliz (HD) hastası (21 kadın, 21 erkek) ve 42 sağlıklı kişi (21 kadın, 21 erkek) çalışmaya alındı. Hastalar (diyalizden önce/sonra) ve kontrol grubundan elde edilen plazma örneklerinde, lipid peroksidasyonu ürünlerinden malondialdehit (MDA) ve plazmanın en önemli antioksidanı olan tiyol düzeyleri tayin edildi. Kontrole göre, HD hastalarında MDA değerleri daha yüksek (3.15±0.63/4.04±1.19 µmol/L); buna karşılık tiyol seviyeleri daha düşük (358±65/214±82 µmol/L) bulundu (p<0.05). HD tedavisiyle hastalarda tiyol değerlerinin arttığı (p<0,05), MDA seviyelerinin ise değişmediği (p>0.05) belirlendi. Diyaliz tedavisini takiben, MDA düzeylerinin kontrole göre hastalarda hala yüksek olduğu (3.15±0.633.15±0.63 / 4.22±2.56 µmol/L) gözlendi (p<0.05). Buna karşılık tiyol seviyeleri bakımından (358±65/310±107 µmol/L), hasta ve kontrol grupları arasında fark olmadığı bulundu (p>0.05). Sonuç olarak, HD hastalarında oksidanantioksidan sistemler arasındaki dengenin bozulduğu ve lipid peroksidasyonuyla karakterize oksidatif stresin meydana geldiği söylenebilir

Keywords

• Hemodiyaliz, lipid peroksidasyonu, oksidatif stres

Malondialdehyde and Thiol Levels in Plasma of Hemodialysis Patients

Abstract

In order to investigate the relationship between oxidative stress and the risk of cardiovascular disease (CVD) observed in chronic renal failure (CRF), especially in patients undergoing hemodialysis (HD), 42 HD patients (21 F, 21 M), aged 16-64 years and 42 healthy volunteers (21 F, 21 M) were included in the study. The levels of malondialdehyde (MDA), one of the lipid peroxidation products, and thiol, the most important plasma antioxidant, were measured in plasma samples obtained from controls and patients, before and after dialysis. When compared to controls, plasma MDA levels were found to be higher (3.15±0.63 vs 4.04±1.19 µmol/L), however thiol levels were lower (358±65 vs 214±82 µmol/L) in HD patients (p<0.05). After the hemodialysis treatment, thiol levels were higher than pre-HD values (p<0.05), although the HD treatment did not affect MDA levels (p>0.05). No significant difference of thiol levels was found between the control group and HD patients (358±65 vs 310±107 µmol/L) after treatment (p>0.05), whereas MDA levels were still higher (3.15±0.63 vs 4.22±2.56 µmol/L) in the HD group (p<0.05). In conclusion, it may be said that there are disturbances in the oxidant-antioxidant balance that may lead to oxidative stress, reflected by lipid peroxidation in HD patients

Keywords

• Hemodialysis, lipid peroxidation, oxidative stress

References

1. Akpolat T, Utaş C. Hemodiyaliz Hekimi El Kitabı. Kayseri, Anadolu Yayıncılık, 2001
2. Shoji T, Nishizawa Y, Kawagishi T, et al. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with sulphydryl compounds and S-nitrosothiols in chronic renal failure patients. Clin Chim Acta 2003, 327:87-94.
3. Wlodek PJ, Iciek MB, Milkowski A, Smolenski OB. Various forms of plasma cysteine and its metabolites in patients undergoing hemodialysis. Clin Chim Acta 2001,304:9-18.
4. Kitiyakara C, Gonin J, Massy Z, Wilcox CS. Non-traditional cardiovascular disease risk factors in end-stage renal disease: oxidative stress and hyperhomocysteinemia. Curr Opin Nephrol Hypertens 2000, 9: 477-487.
5. Chugh SN, Jain S, Agrawal N, Sharma A. Evaluation of oxidative stress before and after haemodialysis in chronic renal failure. J Assoc Physicians India. 2000,48:981-984.
6. Samouilidou E, Grapsa E. Effect of dialysis on plasma total antioxidant capacity and lipid peroxidation products in patients with end- stage renal failure. Blood Purif. 2003, 21:209- 212.
7. Banni S, Lucchi L, Baraldi A, et al. No direct evidence of increased lipid peroxidation in hemodialysis patients. Nephron. 1996, 72:177- 183.
8. Clermont G, Lecour S, Lahet JJ, Siohan P, Vargely C et al. Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. Cardiovasc Res 2000; 47: 618-623.

9. plasma. Bİochim Biophys Acta 1987, 924: 408-419.
10. Halliwell B, Gutteridge JMC. The antioxidants of human extracellular fluids. Arch Biochem Biophys 1990, 280: 1-8
11. Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 2000, 58: 2571-2578.
12. Wlodek PJ, Kurcharczyk J, Sokolovska MM, et al. Alteration in plasma levels of nonprotein